Info
Early-Stage Triple-Negative Breast Cancer Journey Beginning, End, and Everything in Between
- DOI: 10.1200/EDBK_390464 43 (June 19, 2023)
INTRODUCTION THE ROLE OF NEOADJUVANT THERAPY NAC REGIMENS: WHERE DO WE STAND? Intensity and Frequency of Chemotherapy Influence Response The Function of Platinum-Based Therapies in NAC Chemoimmunotherapy Is the Standard of Care in Stage II and III TNBC De-Escalation of Anthracycline-Based Therapies TAILORING POSTNEOADJUVANT THERAPY IN TNBC The Use of PARP Inhibitors in Early-Stage TNBC IDENTIFICATION AND MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS Endocrinopathies Thyroid Dysregulation AI CHECKPOINT INHIBITOR-ASSOCIATED DIABETES MELLITUS IMMUNE-RELATED HYPOPHYSITIS CUTANEOUS IRAES GI IRAES Colitis Gastritis Hepatitis Musculoskeletal irAEs FUTURE DIRECTIONS Using Biomarkers to Optimize Treatment in Early-Stage TNBC CONCLUSION